Nektar Therapeutics
NKTR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $191 | $107 | $423 | $2,476 |
| - Cash | $44 | $35 | $88 | $25 |
| + Debt | $103 | $118 | $131 | $143 |
| Enterprise Value | $250 | $190 | $466 | $2,594 |
| Revenue | $98 | $90 | $92 | $102 |
| % Growth | 9.2% | -2.1% | -9.7% | – |
| Gross Profit | $68 | $53 | $70 | $77 |
| % Margin | 68.8% | 59.3% | 76.5% | 75.6% |
| EBITDA | -$87 | -$243 | -$324 | -$462 |
| % Margin | -88.1% | -269.8% | -351.8% | -453.2% |
| Net Income | -$119 | -$276 | -$368 | -$524 |
| % Margin | -120.9% | -306.3% | -400% | -514% |
| EPS Diluted | -8.68 | -21.79 | -29.51 | -42.9 |
| % Growth | 60.2% | 26.2% | 31.2% | – |
| Operating Cash Flow | -$176 | -$193 | -$304 | -$413 |
| Capital Expenditures | -$1 | -$1 | -$6 | -$15 |
| Free Cash Flow | -$177 | -$193 | -$310 | -$428 |